In a patent infringement appeal filed by Momenta Pharmaceuticals Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals, the Court of Appeals for the Federal Circuit declared some patents for Teva Pharmaceutical Industries Ltd.'s multiple sclerosis (MS) drug, Copaxone (glatiramer acetate injection), to be invalid. Read More
While they are waiting for data from the non-small-cell lung cancer (NSCLC) program with Synta Pharmaceutical Corp.'s heat-shock protein 90 (Hsp90) inhibitor ganetespib, investors got a nice surprise from the Phase II effort in locally advanced or metastatic HER2-positive or triple-negative breast cancer (TNBC). Read More
Protein and antibody drug developer Five Prime Therapeutics Inc. became the newest member of the class of 2013 biotech initial public offerings (IPOs) by filing an S-1 seeking to raise up to $60 million. Read More
While the stars are aligning for the makers of medical countermeasures (MCMs), the space still has a lot of black holes as sponsors await more regulatory direction and try to anticipate what a next-generation program might look like. Read More
LONDON – The first patient has been treated in a Phase I trial of Uniqure BV's gene therapy for Parkinson's disease, with the company's CEO Jörn Aldag personally assisting in the surgery, in which the gene for glial cell line-derived neurotrophic factor (GDNF) was administered directly into the brain. Read More
LONDON – New oral drugs for diverse conditions such as diabetes, osteoporosis, depression and anxiety have edged closer to development as a result of new information about the structure of an important class of hormone receptor. Read More
• Arecor Ltd., of Cambridge, UK, said the UK's innovation agency, the Technology Strategy Board, has given a Proof of Concept award through its Smart program to support research and development of a stable formulation of its flu vaccine, Redee Flu. Read More
• Pfizer Inc., of New York, said it will separate its commercial operations into three business segments in January 2014. One will include inflammation and immunology, CV/metabolic diseases, neuroscience and pain, rare diseases and women's/men's health. Another will encompass vaccines, oncology and consumer health care. Read More
• Entremed Inc., of Rockville, Md., said it started a crossover bioavailability and food effect study of ENMD-2076, an oral Aurora A/angiogenic kinase inhibitor. Read More
